Processa Pharmaceuticals, Inc. (PCSA): Nasdaq/NYSE listing notice — Processa receives second 180-day grace period to regain Nasdaq bid price compliance

Processa Pharmaceuticals, Inc.

Grace period runs until February 2, 2026 to meet $1.00 minimum bid price.
Compliance requires closing bid price ≥ $1.00 for 10 consecutive business days.
Company will consider a reverse stock split if needed to cure deficiency.
Common stock continues trading on Nasdaq Capital Market during the period.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Processa Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

August 7, 2025, the Company received a letter from the Staff notifying that the Company is eligible for a second 180-day period, or until February 2, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the minimum bid price requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure t

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Processa Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-011775

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.